JAKARTA – PT Brigit Biofarmaka Teknologi Tbk (OBAT) has announced its plans for continuous growth, aiming for a 20% increase this year or even higher.

According to an official statement received by IDNFinancials on Monday (13/1), OBAT recorded total sales exceeding IDR 100 billion by the end of 2024, with a net profit reaching IDR 30 billion.

"Back in 2023, our assets were only IDR 30 billion, but we managed to earn a profit of IDR 12 billion. This year [2024], profit has already hit IDR 30 billion, even though our assets are only IDR 50 billion," said Machmud Lutfi Huzain, President Commissioner of OBAT, during a Post-IPO Press Conference on Monday (13/1).

Huzain attributes the impressive 30% net profit margin to efficiency and self-sustaining spirulina cultivation. OBAT's flagship product, spirulina, can be processed into supplements, milk, and even cosmetics for the company's maklon (toll manufacturing) business.

"This nutritious meal program is an opportunity for us because we produce spirulina supplements," Huzain continued. Spirulina milk and neoalgae spirulina are projected to complement the Free Nutritious Meal Program initiated by Prabowo Subianto.

"We have held several discussions regarding this free lunch program, and we are just waiting for final information from the National Nutrition Agency," added Is Heriyanto, President Director of OBAT, in the same event.

Heriyanto also revealed plans to adopt digital marketing strategies to position OBAT as a one-stop maklon service provider.

"With this approach, we are confident that OBAT can surpass the 20% target in line with the projections we have shared," concluded Huzain. (ZH)